DocGo Appoints New CMO, Adds Director

Ticker: DCGO · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1822359

Docgo INC. 8-K Filing Summary
FieldDetail
CompanyDocgo INC. (DCGO)
Form Type8-K
Filed DateMar 8, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $35,000
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, board-changes, governance

Related Tickers: DCGO

TL;DR

DocGo brings in a new CMO and adds a director to the board, effective March 7.

AI Summary

DocGo Inc. announced on March 7, 2024, the appointment of Dr. Yaron Ben-Haim as Chief Medical Officer and the election of Ms. Sarah E. Glickman to its Board of Directors. The company also disclosed compensatory arrangements for its officers. These changes are effective as of March 7, 2024.

Why It Matters

The appointment of a new Chief Medical Officer and a new Board member can signal strategic shifts or enhanced expertise within the company, potentially impacting its future direction and operations.

Risk Assessment

Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events and do not inherently present significant financial risks.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer of DocGo Inc.?

Dr. Yaron Ben-Haim has been appointed as the new Chief Medical Officer of DocGo Inc.

Who has been elected to the Board of Directors of DocGo Inc.?

Ms. Sarah E. Glickman has been elected to the Board of Directors of DocGo Inc.

What is the effective date for these appointments and elections?

The effective date for these appointments and elections is March 7, 2024.

What other information is disclosed in this 8-K filing?

The filing also discloses compensatory arrangements of certain officers.

What was DocGo Inc.'s former company name?

DocGo Inc.'s former company name was Motion Acquisition Corp.

Filing Stats: 969 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-03-08 07:06:05

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Separation and Consulting Agreement, dated Mar ch 7, 202 4 , by and between the Company and Stan Vashovsky. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOCGO INC. By: /s/ Ely D. Tendler Name: Ely D. Tendler Title: General Counsel and Secretary Date: March 8, 2024 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing